Menu
Back to User profile » Professor Pierluigi Paggiaro
Papers published by Professor Pierluigi Paggiaro:
Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
Koopman M, Franssen FME, Gaffron S, Watz H, Troosters T, Garcia-Aymerich J, Paggiaro P, Molins E, Moya M, van Burk L, Maier D, Garcia Gil E, Wouters EFM, Vanfleteren LEGW, Spruit MA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:517-533
Published Date: 8 March 2022
Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
Pavord ID, Chapman KR, Bafadhel M, Sciurba FC, Bradford ES, Schweiker Harris S, Mayer B, Rubin DB, Yancey SW, Paggiaro P
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1755-1770
Published Date: 16 June 2021
Overcoming Barriers to the Effective Management of Severe Asthma in Italy
Paggiaro P, Barbaglia S, Centanni S, Croce D, Desideri E, Giustini S, Micheletto C, Musarra A, Scichilone N, Trama U, Zedda MT, Canonica GW
Journal of Asthma and Allergy 2021, 14:481-491
Published Date: 10 May 2021
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G
Journal of Asthma and Allergy 2020, 13:599-604
Published Date: 10 November 2020
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2545-2558
Published Date: 24 August 2017
Targeted therapy in severe asthma today: focus on immunoglobulin E
Pelaia G, Canonica GW, Matucci A, Paolini R, Triggiani M, Paggiaro P
Drug Design, Development and Therapy 2017, 11:1979-1987
Published Date: 29 June 2017
Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:697-714
Published Date: 5 July 2014